Yifan Biotechnology (688382.SH): Phase III clinical study of Nomelcitinib (D-2570) for moderate-to-severe plaque psoriasis meets primary endpoint

Zhitong Finance APP News, InventisBio (688382.SH) announced that the registrational Phase III clinical study of nomelcitinib (D-2570), a novel oral selective inhibitor targeting TYK2 JH2 independently developed by the company, for the treatment of moderate-to-severe plaque psoriasis has met its primary endpoint and key secondary endpoints. The results of this study mark a milestone progress in the clinical development of nomelcitinib (D-2570) in the field of psoriasis.